In: NEOPLASMA, vol. 53, no. 4
M. P. Mencoboni - S. Tredici - M. Varaldo - G. Queirolo - F. Durand - L. Rebella - V. Galbusera - I. M. Pannacciulli - R. Ghio
Detaily:
Rok, strany: 2006, 333 - 336
O článku:
Systemic therapies employed in patients with metastatic renal cell carcinoma (MRCC) include chemotherapy to
immunomodulatory cytokines (interleukin 2 [IL-2], interferon alpha [INFalpha]), chemoimmunotherapy, adoptive immune
therapy and anti-angiogenic therapy. Despite this range of treatment alternatives, the optimal therapy for MRCC patients is
far from being established. Thus, attempts with novel therapeutic approaches implementing new drug combinations are justified.
We conducted a phase II evaluation of a combination of vinorelbine and IL-2, both at low doses, in 30 patients with
MRCC. The rationale of the combination was to damage the tumor tissue to the extent necessary to make it more
immunogenic while, at the same time, to obtain an efficient immune response through the concomitant administration of
IL-2. The treatment, given in different dose combinations and administration times, resulted feasible, with no renal, neurological
or hematological toxicity. The overall survival of the whole group of patients is higher than that usually observed following
treatment with immunotherapies (18.2 versus 13.3 months, respectively). While the limited number of treated patients
does not allow advancing conclusions on the effective activity of the adopted protocol, the results observed are
encouraging.
Ako citovať:
ISO 690:
Mencoboni, M., Tredici, S., Varaldo, M., Queirolo, G., Durand, F., Rebella, L., Galbusera, V., Pannacciulli, I., Ghio, R. 2006. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma. In NEOPLASMA, vol. 53, no.4, pp. 333-336. 0028-2685.
APA:
Mencoboni, M., Tredici, S., Varaldo, M., Queirolo, G., Durand, F., Rebella, L., Galbusera, V., Pannacciulli, I., Ghio, R. (2006). Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma. NEOPLASMA, 53(4), 333-336. 0028-2685.